Form S-1
Please provide us with supplemental copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, have presented or expect to present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not you retained, or intend to retain, copies of those communications. Please contact Tonya K.Rest of the question
Aldave at (202) 551-3601 to discuss how to submit the materials, if any, to us for our review.
No numbered answer found in the reply. Read the reply ↗
We note you indicate that the prospectus includes market and industry data from industry publications and that those sources generally state that the information they provide has been obtained from sources believed to be reliable, but that the accuracy and completeness of the information are not guaranteed. Please revise to clarify that, notwithstanding the foregoing, you believe that this information is reliable.
No numbered answer found in the reply. Read the reply ↗
We note your disclosure on page 6 that as of December 31, 2021, "95.7% of [your] reinsurance recoverables were either derived from reinsurers rated “A-” (Excellent) by A.M. Best, or better." Please revise for consistency with your disclosure in the table on page 97 where you state that $116,822,000 in reinsurance recoverables, or approximately 21.8% of the total $536,327,000 in reinsurance recoverables, wasRest of the question
attributed to Randall & Quilter and eCaptive PC1-IC, two reinsurers that are "unrated" by the AMB Best Ratings.
No numbered answer found in the reply. Read the reply ↗
Please state the approximate amount intended to be used for each purpose listed in the second sentence of the third paragraph, or tell us why you are unable to do so.
No numbered answer found in the reply. Read the reply ↗
Please disclose the identity of "a third party reinsurer" referenced in the first sentence of this section.
No numbered answer found in the reply. Read the reply ↗
Please tell us why it is appropriate to exclude the entire impact of your loss portfolio transfer (LPT) in your non-GAAP measures when you disclose on page 50 and elsewhere that the LPT relates to business that has been predominantly exited.Rest of the question
For the portions of the business not exited, it appears that the removal of the LPT impacts results in the removal of normal, recurring, cash operating expenses of your business. See Question 100.01 of the Compliance and Disclosure Interpretations on Non-GAAP Financial Measures. In your response, specifically tell us how your adjusted loss ratio presented on page 56 is meaningful if the entire net impact of the LPT is removed when presumably the net earned premiums on business not "predominantly exited" are included in the denominator of the ratio.
No numbered answer found in the reply. Read the reply ↗
Please revise your reconciliations of Adjusted operating income and Underwriting income to describe and quantify the components of the "Other income and (expenses)" adjustment.
No numbered answer found in the reply. Read the reply ↗
Please disclose your counterparties for the "Revolver" and the "Term Loan" described on pages 62 and 63 of the prospectus. In addition, tell us if you have filed these agreements and described their material terms.
No numbered answer found in the reply. Read the reply ↗
We note your discussion about the cyclicality of the insurance industry. Please specify the current state of the insurance industry and, if necessary, add tailored risk factor disclosure. In that regard, please clarify in the risk factor heading, "[t]he insurance business is historically cyclical in nature," where the industry is in the cycle, so that investors may assess the risk.
No numbered answer found in the reply. Read the reply ↗
Please refer to the table on page 97 and disclose the percentage of coverage ceded to each reinsurer and the nature and amount of collateral in trust under the contracts. Reserves, page 98
No numbered answer found in the reply. Read the reply ↗
Please tell us why development related to accident years 2019 and 2020 (and presumably 2018 included in the "Prior" accident year totals) is characterized as relating to the LPT when the LPT relates to policies years 2017 and prior. To the extent that this development relates to exited lines, revise your disclosure to clarify and explain why you continue to incur losses on exited lines.
No numbered answer found in the reply. Read the reply ↗
Please disclose the "third party reinsurer domiciled in Bermuda" referenced in the first sentence of this section or advise. In addition, if this is a material agreement not made in the ordinary course of business, file it as an exhibit to the registration statement or advise why you are not required to do so.
No numbered answer found in the reply. Read the reply ↗
Please advise why you have not also included a separate table for the non-equity incentive plan compensation, which is included as a separate column in your summary compensation table. Refer to Item 402(d) of Regulation S-K.
No numbered answer found in the reply. Read the reply ↗
Once you have an estimated offering price or range, please explain to us how you determined the fair value of the common stock underlying your equity issuances and the reasons for any differences between the recent valuations of your common stock leading up to the IPO and the estimated offering price.Rest of the question
This information will help facilitate our review of your accounting for equity issuances including equity compensation.
The Company previously deferred response to theRead in the reply
Staff’s comment until the Company had an estimated offering price or range. The Company advises the Staff that it has established a price range and provides the following explanation in response to prior Comment 14.
[***] Certain confidential information in this letter, marked by brackets, has been omitted and filed separately with the SEC pursuant to 17 C.F.R.Rest of the answer
§200.83.
Page
REQUESTED
BY SKYWARD SPECIALTY INSURANCE
GROUP, INC.
Preliminary price range
The Company expects to include an anticipated price range in an amendment to the Registration Statement that would be filed shortly before the commencement of the road show for the initial public offering (the “IPO”). That price range will be subject to then-current market conditions, continuing discussions with the underwriters and any other factors affecting the Company or the proposed offering.
Based in part on information provided by the underwriters, the Company currently estimates that the anticipated offering prices to be reflected on the cover of the Company’s preliminary prospectus, if and when issued, would be a within the range of $[***] to $[***] per share of common stock (the “Preliminary
Price Range”), before giving effect to a reverse share split that the Company plans to implement prior to effectiveness of the Registration Statement, which reflects a valuation multiple of 1.0 to 1.3 times the diluted book value of the Company of $[***] per share as of June 30, 2022. For clarity, the Company advises the Staff that, given the volatility of the public trading market and the uncertainty of the timing of the offering, the number of shares of common stock of the Company to be issued in connection with the
IPO remains subject to change.
As is typical in initial public offerings, the
Preliminary Price Range was not derived using a formal determination of fair value, but was determined by the Company in consultation with representatives of the underwriters. Among other factors that were considered in setting the Preliminary Price Range were the following:
· the general conditions of the securities markets and the recent market prices of, and the demand for, publicly-traded common stock of comparable companies;
Company’s historical performance;
· estimates of business potential and earnings prospects for the Company;
· recent performance of IPOs of generally comparable companies; and
· business developments affecting the Company.
The Company respectfully advises the Staff that the Preliminary Price Range represents the Company’s belief of what the indicative price range to be disclosed in the preliminary prospectus may be at the current point in time, but that the actual indicative price range to be included in the preliminary prospectus will not be determined until the Company completes a valuation process with the underwriters. The Preliminary Price Range will be included in the preliminary prospectus, which will be included in an amendment to the Registration Statement prior to the distribution of any preliminary prospectus. The Preliminary Price Range reflects the Company’s evaluation based on the valuation process undertaken to date and may be subject to further change, which may result from various factors, including but not limited to then-current market conditions, continuing discussions with representatives of the underwriters and subsequent business, market and other developments affecting the Company.
Equity issuances
As stated in the Registration Statement, the
Company has granted stock-based awards, consisting of restricted stock and restricted stock units, to certain employees, directors and consultants.
The following table lists the common share awards granted since April 1, 2021, the only share based compensation awards the Company issued in the past 18 months prior to the IPO.
Grant date
Award type
Shares or authorized target common shares
Grant date fair value
May 18, 2021
Restricted stock units
2,788
$
[***]
June 1, 2021
November 5, 2021
15,873
February 25, 2022
Market condition awards
113,981
Performance condition awards
104,859
Restricted share and stock unit awards
550,940
All awards were granted by the Board with a grant date fair value per share of the Company’s common stock determined by the
Company’s Board, with input from management, and contemporaneous third-party valuations.
We engaged a third-party valuation firm to calculate the fair value of our share based compensation awards granted on February 25, 2022 in accordance with guidance in the AICPA’s Valuation of Privately-Held-Company Equity Securities Issued as Compensation - Accounting and Valuation Guide. The third-party valuation firm used
3 methods to determine the enterprise value of the Company: discounted cash flow, guideline public company and similar transactions method.
We weighted the methods based on the valuation inputs for each method to arrive at our enterprise value. The weighting was 45%, 45% and
10% for discounted cash flow, guideline public company and similar transactions method, respectively. The enterprise value was allocated between the preferred and common shares using a call option model. The value attributed to the common shares was subject to a calculated discount for lack of marketability (“DLOM”) of 20% determined using 3 separate put-option models.
The grant date fair value of our share based compensation awards granted on November 5, 2021 was determined based on diluted book value per share, which represents a formula price under ASC 718-10-55-131. We validated our formula price estimates by comparing the formula price to our third-party valuations on our share based compensation awards granted in the first quarter of 2021 and 2022 to within a reasonable range.
The increase in grant date fair value between
November 5, 2021 and February 25, 2022 was primarily driven by underwriting results exceeding budget by $[***] million and $[***] million for Q4 2021 QTD and 2021 YTD, respectively. These resulted in improved forecasts of underwriting results used in our discounted cash flow.
compensation awards granted on February 25, 2022 was within the Preliminary Price Range as determined based on multiples of diluted book value of $[***] per share as of June 30, 2022. Further, our DLOM was 20% with input ranges from 15-25% based on the put-option models.
Removing this discount would yield a fair value of $[***] per share, based on the central estimate of the DLOM, which is $[***] per share or [***]% lower than the high end of the underwriter’s range.
Comparison between Previous Valuations and
Preliminary Price Range
In connection with its efforts to evaluate whether to pursue a public offering in the fourth quarter of 2022, the Company requested that representatives of the underwriters provide the
Company with an estimated range of prices that would be reflected in the preliminary prospectus for the IPO. During September 2022, the
Company, in consultation with the representatives of the underwriters, determined the Preliminary Price Range.
The Company believes that the primary factors contributing to the difference between the fair value of the Company’s common stock reflected in the Company’s valuations since April 1, 2021 (the “Previous Valuations”) and the Preliminary Price Range are as follows:
· The
Previous Valuations were made based on information available as of the dates of those valuations, taking into account, among other factors, the Company’s book value, evaluation of its prospects and determination of comparable companies at that time as well as prevailing market and economic conditions.
· Since
December 2021, the Company has taken significant incremental steps towards the completion of an IPO, including holding “testing the waters” meetings, at which the Company received feedback from potential investors, and publicly filing the Registration Statement.
Preliminary Price Range represents a future price for shares of the Company’s common stock that, if issued in the IPO, will be immediately freely tradable in the public markets, whereas the estimated fair value of the Company’s common stock reflected in the Previous
Valuations appropriately represents a contemporaneous estimate of the fair value of shares that were then illiquid and might never become liquid, and as such, were adjusted for a DLOM, which ranged from a high of 25% to a low of 15% calculated using 3 separate put-option models.
Preliminary Price Range reflects perspectives developed after receiving feedback from institutional investors in “testing the waters” meetings regarding the valuation methodologies that investors may use in evaluating an investment in the Company. The implications of these perspectives for a potential range of offering prices for the IPO were first discussed between the Company’s Board and the representatives of the underwriters on September 9, 2022 after the Previous Valuations had been performed.
In part, the difference between the Preliminary
Price Range and the Previous Valuations reflects the use of a more targeted set of comparable companies and a higher associated enterprise value to revenue multiples in deriving the Preliminary Price Range than was used in the Previous Valuations. The Previous Valuations reflect standard methodologies (discussed above) applied to a relatively broad cross-section of insurance companies. This set of comparable companies had a relatively wide range of enterprise value to revenue multiples, which were measured over the trailing twelve months prior to these companies’ IPOs, and the average multiple of this larger group of companies was lower than the average current enterprise value to revenue multiples of the group of comparable companies relied upon in deriving the Preliminary Price Range. By comparison, the multiples that were the focus on the September 2022 discussions between the Company and the representatives of the underwriters, and that were influential in deriving the Preliminary Price Range, were within a narrower range and were more closely concentrated about a higher average value. These multiples were associated with companies that the Company had learned are more likely to be viewed by investors as relevant comparable companies in light of their growth rates, margins and other factors that investors may view as indicative of the
Company’s future financial performance. Importantly, the selection of these comparable companies reflected not only investor feedback following “testing the waters” meetings, but also the opportunity to assess valuation methodologies and categories of comparable companies over a longer time frame of performance, and with the benefit of other factors that were not known or knowable at the time of the Previous Valuations.
Conclusion
Based on the above discussion, the Company believes that the fair values determined by the Board for the common stock applicable to each stock option are appropriate and demonstrate the good faith efforts of the Board to consider all relevant factors in determining fair value at each valuation date.
Please identify the natural persons who have voting or dispositive power with respect to the shares of the entities listed under 5% and Greater Shareholders. Exclusive Forum, page 141
No numbered answer found in the reply. Read the reply ↗
We note the disclosure here that the federal district court will be the exclusive forum for the resolutions of any complaint asserting a cause of action arising under the Securities Act. Your risk factor disclosure on page 40 under "[o]ur certificate of incorporation and bylaws," seems to indicate that the discussed exclusive forum provision for disputes in the Court of Chancery of the State of Delaware applies toRest of the question
Securities Act claims. Please revise for consistency or advise. Notes to Consolidated Financial Statements 2. Summary of Significant Accounting Policies
No numbered answer found in the reply. Read the reply ↗
If true, please revise your policy disclosure to highlight that compensation for awards with market conditions is not reversed if the service was delivered but the market condition not attained consistent with the guidance in ASC 718-10-30-14 while any compensation for awards with a performance conditions would be reversed if the performance condition ultimately is not achieved consistent with the guidance in ASCRest of the question
718-10-30-12. If your policy does not conform with the referenced guidance, tell us the impact of applying it. 4. Goodwill and Intangible Assets, page F-20
No numbered answer found in the reply. Read the reply ↗
Revise to disclose the facts and circumstances leading to the impairment of goodwill during 2021 and 2020, and the method of determining fair value for the reporting unit used in the impairment caluclations. Refer to ASC 350-20-50-2. 5. Investments, page F-23
No numbered answer found in the reply. Read the reply ↗
Please tell us why the amortized cost and fair value of your held to maturity asset-backed securities are the same at both December 31, 2021 and 2020. In your response, tell us: • when you acquired these securities; and • the market rate of interest for these securities at:o acquisition; o December 31, 2020; and
No numbered answer found in the reply. Read the reply ↗
On page F-26 you disclose that the proceeds from the sales of your held to maturity fixed maturity securities were approximately $0.0 million in 2021 and $7.7 million in 2020. Please tell us whether you actually sold these securities or whether the proceeds are the result of maturities or prepayment on the loans underlying your asset-backed securities.Rest of the question
If you sold any held to maturity securities, provide us your analysis as to how these sales do not taint held to maturity classification for your remaining investments as stipulated in ASC 320-10-35-8 and 35-9. 6. Fair Value Measurements, page F-27
No numbered answer found in the reply. Read the reply ↗
Please revise to describe the inputs and techniques used in determining the fair value of your level 2 invesments by major asset class. Refer to ASC 820-10-50-2.bbb. 13. Temporary Equity and Stockholders' Equity, page F-38
No numbered answer found in the reply. Read the reply ↗
Please provide your analysis supporting classification and valuation of your Series A Convertible Preferred Stock as temporary equity as of December 31, 2020. Also tell us how you accounted for the change in conversion rate from $1.74 per common share to $1.51 per common share at December 31, 2021. Refer to specific guidance in your response. 14. Income Taxes, page F-39
No numbered answer found in the reply. Read the reply ↗
Please tell us why you do not have a larger valuation allowance against your net deferred tax assets at both December 31, 2020 and 2021. In this regard, your accumulated deficit at December 31, 2020 and losses in 2020 appear to be indicative of a history of losses and a significant piece of negative evidence that is difficult to overcome with an apparent one year of profitability in 2021 (see ASC 740-10-30-23).Rest of the question
Given that you did not record a significant valuation allowance reversal in 2020, in your response, also tell us why a significant valuation allowance was not recorded against your deferred tax assets at December 31, 2019. 15. Losses and Loss Adjustment Expenses, page F-41
No numbered answer found in the reply. Read the reply ↗
Please revise the rollforwards of your reserves for losses and LAE beginning at the bottom of page F-41 to correct the apparent footing and decimal placement errors. In this regard, for example, it appears that your net reserves at the beginning of 2021 should be $481,602 thousand, not $48 thousand.
No numbered answer found in the reply. Read the reply ↗
You disclose on page F-46 that your property and commercial auto liability lines contributed 25.1% and 24.2% of your premiums written during 2021. You also state on page F-42 that the prior year loss development of your multi-line and short tail lines was due to commercial auto claims, and favorable loss emergence in your property and accident and health product lines, respectively.Rest of the question
Please tell us your consideration of ASC 944-40-50-4H in determining the level of disaggregation for your incurred and paid loss development tables, as these lines within your tables appear to have both a significant proportion of your business as well as differing development patterns. 16. Premiums, page F-46
No numbered answer found in the reply. Read the reply ↗
Please reconcile the gross written premiums by line presented on page F-46 with your disclosures by line on pages 4 and 83.
No numbered answer found in the reply. Read the reply ↗
Please tell us why the following amounts presented in this schedule are inconsistent with those presented in your financial statements: • The total of 2021 current and prior year losses and loss adjustment expenses of $366,348,000 does not agree with the $354,411,000 presented on the face of your statement of operations on page F-6.Rest of the question
• The total of 2020 current and prior year losses and loss adjustment expenses of $351,398,000 does not agree with the $362,182,000 presented on the face of your • Paid claims and claim adjustment expenses of $249,739,000 in 2021 does not agree with the $237,802,000 needed to properly roll forward your net reserve balance in the table beginning at the bottom of page F-41.
No numbered answer found in the reply. Read the reply ↗
Refer to your disclosure on page 134 under "Transactions with the Westaim Corporation and its affiliates" section. Please file the investment management agreement with Arena Investors as an exhibit to your registration statement or tell us why you have not filed it.
No numbered answer found in the reply. Read the reply ↗
We note your response to our prior comment 16 and reissue in part. Your disclosure in this risk factor seems to indicate that the Court of Chancery of the State of Delaware exclusive forum provision applies to Securities Act claims, whereas your disclosure on page 151, under "Exclusive forum," seems to indicate that the federal district courts of the United States of America shall be the sole and exclusive forum forRest of the question
the resolution of any complaint arising under the Securities Act. Please revise for consistency.
No reply letter found.
We note your response to our prior comment 10 and your revised disclosure. Please also disclose if there are any aggregate limits to the reinsurance coverage for each of your listed lines of business in the table on page 72.
No reply letter found.
We acknowledge your response to prior comment 11. Please address the following regarding the table on page 107: • Revise the Prior and 2020 Accident Year rows in either the 2021 Calendar Year or 2020 to 2021 Development columns to accurately depict development.Rest of the question
In this regard, based on the amounts in the 2021 Calendar Year column, it appears that 2020 to 2021 Development for the Prior accident year would be an unfavorable $27,980,000 instead of $30,980,000 and the 2020 accident year would have unfavorable development of $1,300,000 not favorable development of $1,700,000. • Assuming the $30,980,000 of unfavorable prior accident development in the 2020 to 2021 column is correct, confirm our understanding that $28,000,000 of this development relates to the LPT and the remaining $2,980,000 of development relates to non-LPT it is a mere coincidence that non-LPT development across accident years offsets to zero. Notes to Consolidated Financial Statements 6. Fair Value Measurements, page F-27
No reply letter found.
Your disclosure in the second paragraph of this footnote can be read to imply reliance on your investment managers or pricing vendors. Please revise your filing to provide the names and consents of these experts or revise your disclosure to clarify your responsibility for the valuation of your investments and how you used these experts.Rest of the question
See Question 141.02 of the Compliance and Disclosure Interpretations for Securities Act Sections.
No reply letter found.